Infliximab

A single injection of Infliximab (10 μg/g in 100 μL saline/dose ip) in diabetic TNF-α^+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab^[2].